| Literature DB >> 23634169 |
Heyam M A Sidahmed1, Siddig Ibrahim Abdelwahab, Syam Mohan, Mahmood Ameen Abdulla, Manal Mohamed Elhassan Taha, Najihah Mohd Hashim, A Hamid A Hadi, Jamunarani Vadivelu, Mun Loke Fai, Mawardi Rahmani, Maizatulakmal Yahayu.
Abstract
Cratoxylum arborescens (Vahl) Blume is an Asian herbal medicine with versatile ethnobiological properties including treatment of gastric ulcer. This study evaluated the antiulcerogenic mechanism(s) of α -mangostin (AM) in a rat model of ulcer. AM is a prenylated xanthone derived through biologically guided fractionation of C. arborescens. Rats were orally pretreated with AM and subsequently exposed to acute gastric lesions induced by ethanol. Following treatment, ulcer index, gastric juice acidity, mucus content, histological and immunohistochemical analyses, glutathione (GSH), malondialdehyde (MDA), nitric oxide (NO), and nonprotein sulfhydryl groups (NP-SH) were evaluated. The anti-Helicobacter pylori, cyclooxygenase-2 (COX-2) inhibitory effect, and antioxidant activity of AM were also investigated in vitro. AM (10 and 30 mg/kg) inhibited significantly (P < 0.05) ethanol-induced gastric lesions by 66.04% and 74.39 %, respectively. The compound induces the expression of Hsp70, restores GSH levels, decreases lipid peroxidation, and inhibits COX-2 activity. The minimum inhibitory concentration (MIC) of AM showed an effective in vitro anti-H. pylori activity. The efficacy of the AM was accomplished safely without presenting any toxicological parameters. The results of the present study indicate that the antioxidant properties and the potent anti-H. pylori, in addition to activation of Hsp70 protein, may contribute to the gastroprotective activity of α -mangostin.Entities:
Year: 2013 PMID: 23634169 PMCID: PMC3619625 DOI: 10.1155/2013/450840
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Chemical structure of α-mangostin from Cratoxylum arborescens (Vahl) Blume.
Observed ulcer area, inhibition percentage pH and mucus content stomach.
| Animal group | Pre-treatment (5 mL/kg dose) | pH of gastric content | Mucus content | Ulcer index (mm)2
| Inhibition (%) |
|---|---|---|---|---|---|
| 1 | Tween80 (normal control) | 3.06a ± 0.09 | 1.95a ± 0.06 | ||
| 2 | Ethanol 95% (ulcer control) | 1.67b ± 0.15 | 0.99b ± 0.04 | 482.4a ± 30.89 | |
| 3 | Omeprazole (20 mg/kg) | 3.7a ± 1.14 | 4.5c ± 0.07 | 108b ± 9.60 | 78.42 |
| 4 |
| 4.64d ± 0.1 | 1.875d ± 0.04 | 169.92c ± 75.05 | 66.04 |
| 5 |
| 3.20e ± 0.05 | 3.1e ± 0.01 | 128.16d ± 84.75 | 74.39 |
All values are expressed as mean ± standard error of the mean. Means with different superscripts are significantly different. The mean difference is significant at the 0.05 level. Groups with different superscript alphabets are statistically significant.
Figure 2Gross evaluation of stomachs from various animal groups. Results showed that rats pretreated with α-mangostin (AM) at doses of 10 and 30 mg/kg ((d) and (e), resp.) and omeprazole ((c); 20 mg/kg) had considerably reduced areas of gastric ulcer formation compared to rats pretreated with only Tween80 (ulcer control group, (a)) (magnification: 1.8x).
Effects of α-mangostin (AM) of liver function tests (ALT and AST), gastric MDA, GSH, NP-SH and nitric oxide.
| Animal groups | Pre-treatment | AST | ALT | GSH | MDA | NP-SH | Nitric oxide [NO2 −] μM |
|---|---|---|---|---|---|---|---|
| 1 | Tween80 | 61.06a ± 1.1 | 145.06a ± 1.8 | 1.6a ± 0.03 | 14b ± 0.31 | 0.6a ± 0.09 | 9.2a ± 0.19 |
| 2 | Ethanol 95% | 97b ± 0.15 | 292.2b ± 19.2 | 0.7b ± 0.10 | 28a ± 0.14 | 7.2b ± 0.5 | 3.32b ± 0.21 |
| 3 | Omeprazole (20 mg/kg) | 63a ± 0.76 | 176a ± 4.1 | 1.7a ± 0.03 | 15a ± 0.21 | 1.71a ± 1.4 | 7.7a ± 1.12 |
| 4 |
| 64d ± 1.5 | 173d ± 3.6 | 1.41d ± 0.3 | 14d ± 0.12 | 2.6d ± 0.19 | 6.3d ± 0.14 |
| 5 |
| 59e ± 6.2 | 164e ± 5.0 | 1.7e ± 0.02 | 14e ± 0.11 | 1.40e ± 0.93 | 8.1e ± 0.53 |
Values are presented as mean ± SEM of five rats in each group. Glutathione (GSH) levels, malondialdehyde level (MDA), nitric oxide (NO), alanine transaminase (ALT), aspartame transaminase (AST) and non-protein sulfhydryl groups (NP-SH) were measured in all groups. Groups with different alphabets are statistically different.
Figure 3Histopathological evaluation. Results showed that α-mangostin (AM) at doses of 10 and 30 mg/kg ((d) and (e), resp.) and omeprazole ((c); 20 mg/kg) improved the histopathology of rats' stomach compared to those pretreated with only Tween80 (ulcer control group, (b)). Black arrow indicates severe disruption to the epithelium surface and deep mucosa, while white arrow indicates leukocyte infiltration and edema in the submucosa layer (H and E stain; magnification: 10x).
Figure 4PAS staining for the evaluation of mucus production. Results showed that rats pretreated with α-mangostin (AM) at doses of 10 and 30 mg/kg ((c) and (d), resp.) and omeprazole ((e); 20 mg/kg) showed more PAS-positive mucus as compared to those pretreated with only Tween80 (ulcer control group, (b)) (Magnification: 10x).
Figure 5Immunohistochemical staining of rat gastric tissues with Hsp70 primary antibodies. (a) Gastric tissues from AM (10 mg/kg) pretreated animals; (b) gastric tissues from AM (30 mg/kg) pretreated animals; (c) gastric tissues from ethanol-induced animals; (d) gastric tissues from omeprazole (20 mg/kg) pretreated animals (magnification: 10x).